Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 9/20 | 0.43 |
| ▸ | CA1 | P00915 | 9/20 | 0.43 |
| ▸ | CA2 | P00918 | 9/20 | 0.43 |
| ▸ | CA4 | P22748 | 3/20 | 0.43 |
| ▸ | CA5A | P35218 | 3/20 | 0.43 |
| ▸ | CA7 | P43166 | 3/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.43 |
| ▸ | CA9 | Q16790 | 6/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | P4HB | P07237 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14278404 | 0.84 | TSHR (0.52) | TSHRALDH1A1LMNACA12CA1 | |
| SCHEMBL2454848 | 0.84 | TSHR (0.52) | TSHRALDH1A1LMNACA12CA1 | |
| SCHEMBL2454844 | 0.84 | TSHR (0.52) | TSHRALDH1A1LMNACA12CA1 | |
| SCHEMBL7025660 | 0.83 | TSHR (0.51) | TSHRKDM4EALDH1A1HPGDLMNA | |
| SCHEMBL6303221 | 0.83 | TSHR (0.71) | TSHRKDM4EALDH1A1HPGDLMNA | |
| SCHEMBL21753464 | 0.83 | TSHR (0.51) | TSHRKDM4EALDH1A1HPGDLMNA | |
| SCHEMBL18343982 | 0.82 | TSHR (0.50) | TSHRALDH1A1LMNAKMT2AP4HB | |
| SCHEMBL9393500 | 0.82 | TSHR (0.50) | TSHRALDH1A1LMNAKMT2AP4HB | |
| SCHEMBL6297105 | 0.81 | TSHR (0.48) | TSHRKDM4EALDH1A1HPGDLMNA | |
| SCHEMBL20095195 | 0.80 | TSHR (0.59) | TSHRALDH1A1LMNACA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 267 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240200076-A1 | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, PREPARATION METHOD, AND USE | Suzhou Ribo Life Science Co., Ltd. (CN) | 2024-06-20 | — | — | US | claimed |
| US-11918600-B2 | Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof | Suzhou Ribo Life Science Co., Ltd. (CN) | 2024-03-05 | — | — | US | claimed |
| US-20230313195-A1 | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, PREPARATION METHOD, AND USE | Suzhou Ribo Life Science Co., Ltd. (CN) | 2023-10-05 | — | — | US | claimed |
| US-20230257827-A1 | CONJUGATES AND PREPARATION AND USE THEREOF | Suzhou Ribo Life Science Co., Ltd. (CN) | 2023-08-17 | — | — | US | claimed |
| US-20230193277-A1 | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, PREPARATION METHOD, AND USE | Suzhou Ribo Life Science Co., Ltd. (CN) | 2023-06-22 | — | — | US | claimed |
| US-11660347-B2 | Nucleic acid, composition and conjugate containing same, preparation method, and use thereof | Suzhou Ribo Life Science Co., Ltd. (CN) | 2023-05-30 | — | — | US | claimed |
| US-20230076803-A1 | COMPOUND AND DRUG CONJUGATE, AND PREPARATION METHOD AND USE THEREOF | Suzhou Ribo Life Science Co., Ltd. (CN) | 2023-03-09 | — | — | US | claimed |
| US-20220395526-A1 | NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING SAME, AND PREPARATION METHOD AND USE | Suzhou Ribo Life Science Co., Ltd. (CN) | 2022-12-15 | — | — | US | claimed |
| EP-4023659-A1 | COMPOUND AND DRUG CONJUGATE, AND PREPARATION METHOD AND USE THEREOF | Suzhou Ribo Life Science Co., Ltd. (CN) | 2022-07-06 | — | — | EP | claimed |
| EP-3974532-A1 | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, PREPARATION METHOD, AND USE | Suzhou Ribo Life Science Co., Ltd. (CN) | 2022-03-30 | — | — | EP | claimed |
| EP-3719125-A1 | NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING SAME, AND PREPARATION METHOD AND USE | Suzhou Ribo Life Science Co., Ltd. (CN) | 2020-10-07 | — | — | EP | claimed |
| EP-3719127-A1 | NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING SAME, PREPARATION METHOD, AND USE | Suzhou Ribo Life Science Co., Ltd. (CN) | 2020-10-07 | — | — | EP | claimed |
| EP-3137604-A2 | COMPOSITIONS AND METHODS FOR MODULATING GROWTH HORMONE RECEPTOR EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2017-03-08 | — | — | EP | claimed |
| EP-3137091-A2 | COMPOSITIONS AND METHODS FOR MODULATING PKK EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2017-03-08 | — | — | EP | claimed |
| EP-3137605-A2 | COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2017-03-08 | — | — | EP | claimed |
| US-20160076032-A1 | COMPOSITIONS AND METHODS | ISIS PHARMACEUTICALS, INC. (US) | 2016-03-17 | — | — | US | claimed |
| WO-2015168532-A2 | COMPOSITIONS AND METHODS FOR MODULATING PKK EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-11-05 | — | — | WO | claimed |
| WO-2015168618-A2 | COMPOSITIONS AND METHODS FOR MODULATING GROWTH HORMONE RECEPTOR EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-11-05 | — | — | WO | claimed |
| EP-2751270-A1 | OLIGOMER-CONJUGATE COMPLEXES AND THEIR USE | Isis Pharmaceuticals, Inc. (US) | 2014-07-09 | — | — | EP | claimed |
| WO-2013033230-A1 | OLIGOMER-CONJUGATE COMPLEXES AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11918600-B2 | Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof | NSUN2, SLC10A1, BCDIN3D | TSHR 2222/4885KDM4E 2535/4885ALDH1A1 3651/4885 |
| US-20220395526-A1 | NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING SAME, AND PREPARATION METHOD AND USE | NSUN2, RNGTT, ADAR | TSHR 3668/4885KDM4E 2673/4885ALDH1A1 3468/4885 |
| US-20240200076-A1 | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, PREPARATION METHOD, AND USE | PNP, NTPCR, RNASE1 | TSHR 2783/4885KDM4E 4158/4885ALDH1A1 1228/4885 |
| US-11660347-B2 | Nucleic acid, composition and conjugate containing same, preparation method, and use thereof | APOB, C1QBP, APOL1 | TSHR 3909/4885KDM4E 3824/4885ALDH1A1 3395/4885 |
| US-20230193277-A1 | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, PREPARATION METHOD, AND USE | F13A1, F13B, F11 | TSHR 3090/4885KDM4E 3618/4885ALDH1A1 3143/4885 |
| US-20230076803-A1 | COMPOUND AND DRUG CONJUGATE, AND PREPARATION METHOD AND USE THEREOF | ABCG2, ABCB1, SLC10A1 | TSHR 3201/4885KDM4E 3118/4885ALDH1A1 278/4885 |
| US-20160076032-A1 | COMPOSITIONS AND METHODS | FUT6, FUT5, GNE | TSHR 4110/4885KDM4E 3543/4885ALDH1A1 1681/4885 |
| US-20230313195-A1 | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, PREPARATION METHOD, AND USE | PCSK9, PCSK7, PCSK6 | TSHR 4123/4885KDM4E 1680/4885ALDH1A1 4386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.